Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data
Mahmoud Reza Ashrafi, Marzieh Babaee, Seyed Saeed Hashemi Nazari, Mohammad Barzegar, Mohammadreza Ghazavi, Mehran Beiraghi Toosi, Shahriar Nafissi, Soroor Inaloo, Gholamreza Zamani Ghaletaki, Farzad Fatehi, Ramin Heshmat, Masood Ghahvechi Akbari, Alireza Abdi, Hassan Bakhtiary, Hadi Montazerlotfelah · 2024
Read Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data by Mahmoud Reza Ashrafi, Marzieh Babaee, Seyed Saeed Hashemi Nazari, Mohammad Barzegar, Mohammadreza Ghazavi, Mehran Beiraghi Toosi, Shahriar Nafissi, Soroor Inaloo, Gholamreza Zamani Ghaletaki, Farzad Fatehi, Ramin Heshmat, Masood Ghahvechi Akbari, Alireza Abdi, Hassan Bakhtiary, Hadi Montazerlotfelah (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13108001.txt.
Description
BackgroundThree medications have been approved for spinal muscular atrophy (SMA) treatment. No head-to-head clinical trials have directly compared the efficacy of nusinersen and risdiplam. We compare the efficacy of them in Type 2 and 3 SMA patients, with 6 months of follow-up.MethodsA multicenter cohort study was conducted.
Catalog record
| CREATOR | Mahmoud Reza Ashrafi, Marzieh Babaee, Seyed Saeed Hashemi Nazari, Mohammad Barzegar, Mohammadreza Ghazavi, Mehran Beiraghi Toosi, Shahriar Nafissi, Soroor Inaloo, Gholamreza Zamani Ghaletaki, Farzad Fatehi, Ramin Heshmat, Masood Ghahvechi Akbari, Alireza Abdi, Hassan Bakhtiary, Hadi Montazerlotfelah |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |